Pharmaceutical policy in the UK involves a trade-off between the interest of the National HealthService in controlling expenditure on drugs and the interest of the pharmaceutical industry inproviding an incentive for research and development. Since 1957, the Pharmaceutical PriceRegulation Scheme...

The regulation of drug prices is an excellent example of the type of tensions that are emerging inthe UK's new system of multi-level governance. Both the benefits and regulatory burden of thePharmaceutical Price Regulation Scheme (PPRS) are regionally concentrated. However, thoseregional...

Biofuels are increasingly being produced and consumed as a partial substitute to fossil-fuel based transport fuels in the fight against climate change. One policy introduced recently by some countries to help ensure biofuels perform better than fossil fuels environmentally is sustainability...

The Trans Pacific Partnership Agreement (TPPA) is one of a new generation of ‘deep’ preferential trade and investment agreements that will extend many of the provisions seen in previous agreements. This paper presents a prospective policy analysis of the likely text of the TPPA, with...

There have been steep rises in the price of some generic drugs since September 1998. These rises have been the subject of an inquiry by the House of Commons Select Committee on Health. This article comments on the pricing of generic drugs and suggests possible solutions to the recent price...